Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/16532
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBOSETTI, Rita-
dc.contributor.authorMARNEFFE, Wim-
dc.contributor.authorVEREECK, Lode-
dc.date.accessioned2014-03-28T08:31:34Z-
dc.date.available2014-03-28T08:31:34Z-
dc.date.issued2013-
dc.identifier.citationNanomedicine, Barcelona, 11-12 April 2013-
dc.identifier.urihttp://hdl.handle.net/1942/16532-
dc.language.isoen-
dc.titleAssessing the need of quality-adjusted cost-effectiveness studies of nanotechnological cancer therapies-
dc.typeConference Material-
local.bibliographicCitation.conferencedate2013, April 11-12-
local.bibliographicCitation.conferencenameNanomedicine-
local.bibliographicCitation.conferenceplaceBarcelona-
local.bibliographicCitation.jcatC2-
local.type.refereedRefereed-
local.type.specifiedConference Poster-
item.fulltextNo Fulltext-
item.contributorBOSETTI, Rita-
item.contributorMARNEFFE, Wim-
item.contributorVEREECK, Lode-
item.fullcitationBOSETTI, Rita; MARNEFFE, Wim & VEREECK, Lode (2013) Assessing the need of quality-adjusted cost-effectiveness studies of nanotechnological cancer therapies. In: Nanomedicine, Barcelona, 11-12 April 2013.-
item.accessRightsClosed Access-
Appears in Collections:Research publications
Show simple item record

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.